Private Advisor Group LLC Buys 159 Shares of Regeneron Pharmaceuticals, Inc. (REGN)

Private Advisor Group LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,393 shares of the biopharmaceutical company’s stock after acquiring an additional 159 shares during the quarter. Private Advisor Group LLC’s holdings in Regeneron Pharmaceuticals were worth $2,059,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. raised its stake in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares during the last quarter. FNY Partners Fund LP raised its stake in Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the last quarter. IFP Advisors Inc raised its stake in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 96 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $206,000. 66.67% of the stock is currently owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at $372.34 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The company has a market capitalization of $40,651.70, a PE ratio of 32.76, a PEG ratio of 1.49 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period last year, the firm earned $3.13 EPS. The company’s quarterly revenue was up 23.0% on a year-over-year basis. analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

In related news, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now directly owns 11,000 shares in the company, valued at approximately $4,950,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. 10.80% of the stock is owned by company insiders.

A number of equities analysts recently issued reports on REGN shares. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reiterated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a research note on Thursday, November 16th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $467.84.

ILLEGAL ACTIVITY NOTICE: “Private Advisor Group LLC Buys 159 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/06/private-advisor-group-llc-buys-159-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit